Guide
According to EvaluatePharma, cancer is the most sold area of ​​treatment. It is predicted that by 2022, global cancer treatment sales will reach 192.2 billion US dollars, while the cancer drug market share will also grow to 17.5%. In this article, Xiao Bian summarizes the top ten cancer drug rankings in the first three quarters of 2017.
#10. Velcade® (bortezomib)
Vendor: Johnson & Johnson and Takeda Pharmaceutical
Drug type: proteasome inhibitor
Indications: multiple myeloma, mantle cell lymphoma
2017 Q1-Q3 quarter sales: 1.78 billion US dollars (Johnson 843 million + Takeda 937 million US dollars)
2016 Q1-Q3 quarter sales: 1.876 billion US dollars (Johnson 950 million + Takeda 926 million US dollars)
Percent change: -5.1%
#9. Ibrance® (Pabosini)
Seller: Pfizer
Drug Type: Kinase Inhibitor
Indications: Treatment for female patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer after receiving endocrine therapy.
2017 Q1-Q3 quarter sales: $2.41 billion
2016 Q1-Q3 quarter sales: $ 1.492 billion
Percent change: 61.5%
#8. Keytruda® (Partamumab)
Seller: Merck
Drug Type: PD-1 Antibody
Indications: melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, Hodgkin's lymphoma, bladder cancer, high microsatellite instability cancer, gastric cancer.
2017 Q1-Q3 quarter sales: $2.512 billion
2016 Q1-Q3 quarter sales: $919 million
Percentage change: 173.3%
#7. Imbruvica® (Ibrutinib)
Seller: Johnson & Johnson and Aberdeen
Drug Type: Kinase Inhibitor
Indications: Mantle cell lymphoma (MCL) has received at least one previous treatment; chronic lymphocytic leukemia (CLL) has received at least one previous treatment; chronic lymphocytic leukemia has a 17p deficiency.
Sales in Q1-Q3 2017: $3.236 billion (Johnson $1.371 billion + Aberdeen $1.865 billion)
2016 Q1-Q3 quarter sales: 2.226 billion US dollars (Johnson 905 million US dollars + Aibowei 1.321 billion US dollars)
Percent change: 45.4%
#6. Opdivo (纳æ¦å•æŠ—)
Seller: BMS
Drug Type: PD-1 Antibody
Indications: melanoma, metastatic non-small cell lung cancer (NSCLC), advanced renal cell carcinoma, classic Hodgkin's lymphoma, head and neck squamous cell carcinoma, bladder cancer, colorectal cancer and hepatocellular carcinoma.
2017 Q1-Q3 quarter sales: $3.587 billion
2016 Q1-Q3 quarter sales: $2.464 billion
Percentage change: 45.6%
#5. Neulasta/Peglasta (Peugesteen) and Neupogen/Gran (Fogstone)
Seller: Anjin and Kyowa Hakko Kirin2
Indications: For patients with non-myeloid malignancies, after induction or consolidation chemotherapy in patients with acute myeloid leukemia (AML), the drug can reduce the duration of neutrophil recovery and fever, and reduce chemotherapy neutrality after bone marrow transplantation. The duration of clinical sequelae associated with neutropenia and neutropenia.
2017 Q1-Q3 quarter sales: 3.864 billion US dollars, including Neusta (Amgen) 3.42 billion US dollars, Neupogen (Anjin) 423 million US dollars and Kyowa Hakko Kirin total 2.4 billion yen ($2,210.0 million)
2016 Q1-Q3 quarter sales: 4.151 billion US dollars, including Neulasta (Anjin) 3.532 billion US dollars, Neupogen (Anjin) 592 million US dollars and Kyowa Hakko Kirin total 3.1 billion yen ($27.788 million)
Percent change: -6.9%
#4. Avastin (Bevacizumab)
Vendor: Roche (Genentech)
Drug Type: Recombinant Humanized Monoclonal Antibody
Indications: metastatic colorectal cancer, non-squamous cell non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, cervical cancer, and recurrent ovarian epithelial cancer, fallopian tube cancer or primary peritoneal cancer.
2017 Q1-Q3 quarter sales: 4.997 billion Swiss francs ($5.121 billion)
2016 Q1-Q3 quarter sales: 5.114 billion Swiss francs ($5.241 billion)
Percent change: -2.3%
#3. Herceptin (trastuzumab)
Vendor: Roche
Drug type: HER2/neu receptor antagonist
Indications: HER2 overexpressed metastatic breast cancer, HER2 overexpressed metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.
Q1-Q3 quarter sales for 2017: 5.233 billion Swiss francs ($5.363 billion)
2016 Q1-Q3 quarter sales: 5.125 billion Swiss francs ($5.252 billion)
Percent change: 2.1%
#2. Rituxan® (Rituximab, MabThera)
Vendors: Genentech and Biogen
Drug Type: CD20-targeted cytolytic antibody
Indications: non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis (RA), Wegener's granulomatosis (WG), microscopic polyangiitis (MPA).
2017 Q1-Q3 quarter sales: 5.62 billion Swiss francs ($5.76 billion)
2016 Q1-Q3 quarter sales: 5.484 billion Swiss francs ($5.62 billion)
Percent change: 2.5%
#1. Revlimid® (lenalidomide)
Seller: Celgene
Drug Type: Thalidomide Analog
Indications: multiple myeloma, recurrent and refractory mantle cell lymphoma.
2017 Q1-Q3 quarter sales: $ 5.999 billion
2016 Q1-Q3 quarter sales: $5.166 billion
Percent change: 16.1%
Shanghai Chuangsai Technology has excellent performance, interleukin cytokines, fetal bovine serum, electrophoresis equipment scientific instruments, raw material drug standards, chemical reagents, cell culture consumables, Shanghai Chuangsai, mass products special promotions, welcome to inquire!
Portable Water Bottle For Pets
The two-in-one design of water and grain cups realizes the stratification of water and grain. The O-shaped drinking trough and the feeding bowl provide a larger feeding area for pets. It has an activated carbon filter element that can absorb impurities in the water, not only clean, every mouth They all drink at ease.
Portable Water Bottle For Pets,Portable Pet Drinking Fountain,Pet Drinking Fountain,Pet Water Bottle
DongGuan Lucky Pet Products Co., Ltd. , https://www.dgpetproduct.com